Back to top
more

Aclaris Therapeutics (ACRS)

(Delayed Data from NSDQ)

$1.91 USD

1.91
2,043,968

-0.04 (-2.05%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $1.88 -0.03 (-1.57%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (104 out of 245)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength?

by Zacks Equity Research

Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Aclaris (ACRS) delivered earnings and revenue surprises of 0.00% and +14.42%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Aclaris (ACRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Aclaris (ACRS) delivered earnings and revenue surprises of 29.41% and 65.15%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aclaris (ACRS) delivered earnings and revenue surprises of 68.75% and 313.05%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs

by Zacks Equity Research

Aclaris stock surges on inking an exclusive license agreement with Biosion for global rights to two of the latter's pipeline candidates, BSI-045B and BSI-502.

Zacks Equity Research

Aclaris Therapeutics (ACRS) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Aclaris (ACRS) delivered earnings and revenue surprises of -37.50% and 47.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how BellRing Brands (BRBR) and Aclaris Therapeutics (ACRS) have performed compared to their sector so far this year.

Zacks Equity Research

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aclaris (ACRS) delivered earnings and revenue surprises of 21.05% and 58.69%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Aclaris Therapeutics (ACRS) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Zacks Equity Research

SAGE Rides on Zurzuvae Sales, Pipeline Setbacks a Concern

by Zacks Equity Research

Sage Therapeutics' (SAGE) Zurzuvae, approved for treating postpartum depression, holds an excellent commercial opportunity. The recent pipeline setbacks are, however, an overhang.

Zacks Equity Research

Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Adma Biologics (ADMA) and Aclaris Therapeutics (ACRS) have performed compared to their sector so far this year.

Zacks Equity Research

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aclaris (ACRS) delivered earnings and revenue surprises of 14.29% and 20.62%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

BioCryst (BCRX) delivered earnings and revenue surprises of 26.09% and 8.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?

by Zacks Equity Research

Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.

Zacks Equity Research

Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Aclaris Therapeutics (ACRS) and ASLAN Pharmaceuticals Ltd. (ASLN) have performed compared to their sector so far this year.

Zacks Equity Research

Aclaris (ACRS) Upgraded to Buy: Here's Why

by Zacks Equity Research

Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.

Zacks Equity Research

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aclaris (ACRS) delivered earnings and revenue surprises of 18.92% and 344.14%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 5.66% and 20.16%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pacira (PCRX) Earnings Expected to Grow: What to Know Ahead of Q4 Release

by Zacks Equity Research

Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Will Aclaris Therapeutics (ACRS) Report Negative Q4 Earnings? What You Should Know

by Zacks Equity Research

Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?

by Zacks Equity Research

Here is how Aclaris Therapeutics (ACRS) and Akoya Biosciences (AKYA) have performed compared to their sector so far this year.

Zacks Equity Research

Aclaris (ACRS) Stock Rises on Appointment of New Interim CEO

by Zacks Equity Research

Aclaris (ACRS) appoints Neal Walker as interim CEO after current CEO, Douglas Manion, steps down from his role. Shares rise.